Anthem Biosciences Ltd
Anthem Biosciences Ltd (ANTHEM) last reported results for the quarter ended Jun 2026, with sales of ₹418 crore and net profit of ₹120 crore. The stock last traded at ₹884, a market capitalisation of ₹49,774 crore, on a P/E of 83.9. Over the past 52 weeks the stock has ranged between ₹579 and ₹978. Figures are as of 6 Oct 2026 and are not real time.
Anthem Biosciences Ltd share price and key metrics
- Current price
- ₹884
- Market cap
- ₹49,774 cr
- Stock P/E
- 83.9
- Book value
- ₹54.2
- ROE
- 22.3%
- ROCE
- 30.4%
- Dividend yield
- 0.23%
- 52w high / low
- 978/579
Metrics as of 6 Oct 2026. Not real time.
Track Anthem Biosciences Ltd
Cruxal reads every Anthem Biosciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Anthem Biosciences Ltd growth and returns
- 10 Years
- %
- 5 Years
- 14%
- 3 Years
- 26%
- TTM
- -2%
- 10 Years
- %
- 5 Years
- 17%
- 3 Years
- 21%
- TTM
- 18%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- 1 Year
- 11%
- 10 Years
- %
- 5 Years
- 23%
- 3 Years
- 21%
- Last Year
- 22%
Anthem Biosciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹418 cr, down 22.6% from ₹540 cr a year earlier. Net profit was ₹120 cr, down 11.8% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 525 | 498 | 483 | 540 | 550 | 423 | 611 | 418 |
| Expenses | 330 | 338 | 288 | 349 | 332 | 266 | 344 | 268 |
| Operating profit | 195 | 160 | 195 | 191 | 218 | 157 | 267 | 151 |
| OPM % | 37% | 32% | 40% | 35% | 40% | 37% | 44% | 36% |
| Other income | 28 | 24 | 14 | 23 | 48 | 8 | 52 | 25 |
| Interest | 4 | 3 | 1 | 2 | 3 | 0 | 2 | 1 |
| Depreciation | 20 | 20 | 30 | 26 | 34 | 35 | 40 | 30 |
| Profit before tax | 200 | 161 | 178 | 186 | 230 | 130 | 278 | 145 |
| Tax % | 19% | 23% | 54% | 27% | 24% | 29% | 32% | 17% |
| Net profit | 162 | 124 | 83 | 136 | 173 | 93 | 190 | 120 |
| EPS (₹) | 2.90 | 2.22 | 1.48 | 2.42 | 3.09 | 1.65 | 3.38 | 2.13 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Anthem Biosciences Ltd annual results
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 633 | 1,103 | 1,231 | 1,057 | 1,419 | 1,845 | 2,124 | 2,002 |
| Operating profit | 182 | 408 | 565 | 431 | 506 | 672 | 834 | 793 |
| OPM % | 29% | 37% | 46% | 41% | 36% | 36% | 39% | 40% |
| Net profit | 93 | 271 | 406 | 385 | 367 | 451 | 592 | 576 |
| EPS (₹) | 110.62 | 319.74 | 462.09 | 6.75 | 6.57 | 8.07 | 10.54 | 10.25 |
TTM is the trailing twelve months to the most recent quarter.
Anthem Biosciences Ltd balance sheet
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity capital | 8 | 8 | 9 | 114 | 112 | 112 | 112 |
| Reserves | 413 | 693 | 1,346 | 1,627 | 1,813 | 2,298 | 2,930 |
| Borrowings | 159 | 100 | 35 | 126 | 239 | 113 | 54 |
| Other liabilities | 207 | 232 | 228 | 148 | 235 | 284 | 333 |
| Total liabilities | 787 | 1,034 | 1,619 | 2,014 | 2,398 | 2,808 | 3,429 |
| Fixed assets | 306 | 361 | 329 | 449 | 483 | 705 | 783 |
| CWIP | 50 | 19 | 154 | 164 | 345 | 297 | 264 |
| Investments | 99 | 209 | 273 | 499 | 472 | 433 | 1,007 |
| Other assets | 333 | 445 | 863 | 902 | 1,099 | 1,373 | 1,374 |
| Total assets | 787 | 1,034 | 1,619 | 2,014 | 2,398 | 2,808 | 3,429 |
As reported by the company. Total assets equal total liabilities by construction.
Anthem Biosciences Ltd cash flow
| ₹ crore | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 166 | 278 | 333 | 306 | 140 | 271 | 844 |
| Cash from investing | -109 | -196 | -205 | -376 | -221 | -147 | -702 |
| Cash from financing | -48 | -63 | 181 | 64 | -77 | -136 | -40 |
| Net cash flow | 9 | 18 | 308 | -6 | -158 | -12 | 103 |
| Free cash flow | 119 | 159 | 307 | 112 | -156 | 12 | 637 |
| CFO / operating profit | 116% | 85% | 81% | 98% | 51% | 64% | 126% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Anthem Biosciences Ltd operating ratios
| Per year | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| ROCE % | — | 55% | 51% | 28% | 24% | 28% | 30% |
| Debtor days | 61 | 84 | 97 | 95 | 126 | 89 | 101 |
| Inventory days | 186 | 29 | 52 | 139 | 129 | 167 | 56 |
| Days payable | 87 | 50 | 50 | 77 | 61 | 54 | 34 |
| Cash conversion cycle | 160 | 63 | 99 | 156 | 193 | 202 | 124 |
| Working capital days | 20 | 27 | 75 | 112 | 128 | 134 | 92 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Anthem Biosciences Ltd shareholding pattern
Promoters held 71.42% at Jun 2026, down from 74.69% at Sep 2025. FIIs 2.57% and DIIs 13.48%.
| % held | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Promoters | 74.69% | 74.69% | 74.67% | 71.42% |
| FIIs | 1.66% | 1.37% | 1.28% | 2.57% |
| DIIs | 7.21% | 7.60% | 11.55% | 13.48% |
| Public | 16.42% | 16.34% | 12.48% | 12.52% |
| No. of shareholders | 2,17,681 | 1,99,492 | 1,80,220 | 1,73,273 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Anthem Biosciences Ltd corporate filings
- Compliance Certificate under Reg 74(5) of DP RegulationsCompany Updatelow impact
- Intimation of closure of Trading Window for Q2FY27Insider Trading / SASTlow impact
- Anthem Biosciences Ltd announces settlement of upside sharing arrangementCompany Updatelow impact
Cruxal's analysis: The company has formally intimated the settlement of an 'Upside Sharing Arrangement'. No…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.